Here we demonstrate that INCB081776, currently in phase 1 clinical trials, is a highly selective inhibitor of AXL and MERTK (17) and functions to inhibit AXL and MERTK through immunomodulatory as well as tumor-directed signaling mechanisms. The gene discussed is MERTK; the disease is neoplasm.